Inclusion-cell (I-cell) disease, also referred to as mucolipidosis II (ML II), is part of the lysosomal storage disease family and results from a defective phosphotransferase (an enzyme of the Golgi apparatus). This enzyme transfers phosphate to mannose residues on specific proteins. Mannose-6-phosphate serves as a marker for proteins to be targeted to lysosomes within the cell. Without this marker, proteins are instead secreted outside the cell, which is the default pathway for proteins moving through the Golgi apparatus. Lysosomes cannot function without these proteins, which function as catabolic enzymes for the normal breakdown of substances (e.g. oligosaccharides, lipids, and glycosaminoglycans)  in various tissues throughout the body (i.e. fibroblasts). As a result, a buildup of these substances occurs within lysosomes because they cannot be degraded, resulting in the characteristic I-cells, or "inclusion cells" seen microscopically. In addition, the defective lysosomal enzymes normally found only within lysosomes are instead found in high concentrations in the blood, but they remain inactive at blood pH (around 7.4) because they require the low lysosomal pH 5 to function. Signs and symptoms
Mucolipidosis II (ML II) is a particularly severe form of ML that has a significant resemblance to another mucopolysaccharidosis called Hurler syndrome. Generally only 
laboratory testing can distinguish the two as the presentation is so similar, with high plasma concentrations of lysosomal enzymes, often fatal in childhood. Typically, by the age of 6 months, failure to thrive and developmental delays are obvious signs of this disorder.
Potassium permanganate dilute solution soaks – also popular, and used to dry out the vesicles, and kill off superficial Staphylococcus aureus, but it can also be very painful. Undiluted it may cause significant burning. Dapsone (diamino-diphenyl sulfone), an antibacterial, has been recommended for the treatment of dyshidrosis in some chronic cases. Antihistamines: Fexofenadine up to 180 mg per day. Alitretinoin (9-cis-retinoic acid) has been approved for prescription in the UK. It is specifically used for chronic hand and foot eczema. It is made by Basilea of Switzerland (BAL 4079). Systemic steroids can be taken orally to treat especially acute and severe cases of dyshidrosis. Epidemiology
About 1 in 2,000 people are affected in Sweden. Males and females appear to be affected equally. Synonyms
Dyshidrosis is also known as pompholyx, a term originating from the Greek word for "bubble". See also
Dermatitis herpetiformis – a similar condition caused by celiac and often mistaken for dyshidrosis. Epidermolysis bullosa – a genetic disorder that causes similar, albeit more severe, symptoms to those of dyshidrosis. References
External links

Images of dyshidrotic eczema at Skinsight
Pompholyx at DermNet NZ (New Zealand Dermatological Society Incorporated)